Drug Profile
PRV 3279
Alternative Names: Anti-CD32B-anti-CD79B-bispecific-monoclonal-antibody; CD32BxCD79B; MGD 010; PRV-3279Latest Information Update: 02 May 2023
Price :
$50
*
At a glance
- Originator MacroGenics
- Developer Provention Bio
- Class Anti-inflammatories; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Fc gamma receptor IIA antagonists; Fc gamma receptor IIB antagonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Systemic lupus erythematosus
- Preclinical Autoimmune disorders